Supplementary Figure 11 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Year: 2023
Type: supplementary-materials
Abstract: MRD testing in newly diagnosed, metastatic BC patients. (A) Number of mutations detected for each patient's sample. Each patient's panel was additionally applied to healthy donors as a specificity check. (B) Tumor fraction estimates for each patient's sample over course of treatment, stratified by clinical benefit. (C) Tumor fraction fold change between first two timepoints, stratified by clinical benefit. Confidence intervals were re-calculated using the Delta Method. (D) Tumor fractions for MRD+ samples split by the minimum fingerprint size required to still detect MRD.
Authors: Heather A. Parsons, Justin Rhoades, Sarah C. Reed, Gregory Gydush, Priyanka Ram, Pedro Exman, Kan Xiong, Christopher C. Lo, Tianyu Li, Mark Fleharty, Gregory J. Kirkner, Denisse Rotem, Ofir Cohen, Fangyan Yu, Mariana Fitarelli-Kiehl, Ka Wai Leong, Melissa E. Hughes, Shoshana M. Rosenberg, Laura C. Collins, Kathy D. Miller, Brendan Blumenstiel, Lorenzo Trippa, Carrie Cibulskis, Donna S. Neuberg, Matthew DeFelice, Samuel S. Freeman, Niall J. Lennon, Nikhil Wagle, Gavin Ha, Daniel G. Stover, Atish D. Choudhury, Gad Getz, Eric P. Winer, Matthew Meyerson, Nancy U. Lin, Ian Krop, J. Christopher Love, G. Mike Makrigiorgos, Ann H. Partridge, Erica L. Mayer, Todd R. Golub, Viktor A. Adalsteinsson
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362410978